935 related articles for article (PubMed ID: 33471991)
21. Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants.
Mundt E; Mabey B; Rainville I; Ricker C; Singh N; Gardiner A; Manley S; Slavin T
Cancer Genet; 2023 Nov; 278-279():84-90. PubMed ID: 37839337
[TBL] [Abstract][Full Text] [Related]
22. Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
Sepahi I; Faust U; Sturm M; Bosse K; Kehrer M; Heinrich T; Grundman-Hauser K; Bauer P; Ossowski S; Susak H; Varon R; Schröck E; Niederacher D; Auber B; Sutter C; Arnold N; Hahnen E; Dworniczak B; Wang-Gorke S; Gehrig A; Weber BHF; Engel C; Lemke JR; Hartkopf A; Nguyen HP; Riess O; Schroeder C
BMC Cancer; 2019 Aug; 19(1):787. PubMed ID: 31395037
[TBL] [Abstract][Full Text] [Related]
23. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
[TBL] [Abstract][Full Text] [Related]
24. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
[TBL] [Abstract][Full Text] [Related]
25. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
[TBL] [Abstract][Full Text] [Related]
26. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
27. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
[TBL] [Abstract][Full Text] [Related]
28. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
Shimelis H; LaDuca H; Hu C; Hart SN; Na J; Thomas A; Akinhanmi M; Moore RM; Brauch H; Cox A; Eccles DM; Ewart-Toland A; Fasching PA; Fostira F; Garber J; Godwin AK; Konstantopoulou I; Nevanlinna H; Sharma P; Yannoukakos D; Yao S; Feng BJ; Tippin Davis B; Lilyquist J; Pesaran T; Goldgar DE; Polley EC; Dolinsky JS; Couch FJ
J Natl Cancer Inst; 2018 Aug; 110(8):855-862. PubMed ID: 30099541
[TBL] [Abstract][Full Text] [Related]
29. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on
Lee A; Mavaddat N; Cunningham A; Carver T; Ficorella L; Archer S; Walter FM; Tischkowitz M; Roberts J; Usher-Smith J; Simard J; Schmidt MK; Devilee P; Zadnik V; Jürgens H; Mouret-Fourme E; De Pauw A; Rookus M; Mooij TM; Pharoah PP; Easton DF; Antoniou AC
J Med Genet; 2022 Dec; 59(12):1206-1218. PubMed ID: 36162851
[TBL] [Abstract][Full Text] [Related]
30. Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
Lu HM; Li S; Black MH; Lee S; Hoiness R; Wu S; Mu W; Huether R; Chen J; Sridhar S; Tian Y; McFarland R; Dolinsky J; Tippin Davis B; Mexal S; Dunlop C; Elliott A
JAMA Oncol; 2019 Jan; 5(1):51-57. PubMed ID: 30128536
[TBL] [Abstract][Full Text] [Related]
31. Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes.
Kurian AW; Abrahamse P; Ward KC; Hamilton AS; Deapen D; Berek JS; Hoang L; Yussuf A; Dolinsky J; Brown K; Slavin T; Hofer TP; Katz SJ
JCO Precis Oncol; 2021; 5():. PubMed ID: 34977446
[TBL] [Abstract][Full Text] [Related]
32. Breast Cancer Risk in Women from Ghana Carrying Rare Germline Pathogenic Mutations.
Ahearn TU; Choudhury PP; Derkach A; Wiafe-Addai B; Awuah B; Yarney J; Edusei L; Titiloye N; Adjei E; Vanderpuye V; Aitpillah F; Dedey F; Oppong J; Osei-Bonsu EB; Duggan MA; Brinton LA; Allen J; Luccarini C; Baynes C; Carvalho S; Dunning AM; Davis Lynn BC; Chanock SJ; Hicks BD; Yeager M; Chatterjee N; Biritwum R; Clegg-Lamptey JN; Nyarko K; Wiafe S; Ansong D; Easton DF; Figueroa JD; Garcia-Closas M
Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1593-1601. PubMed ID: 35654374
[TBL] [Abstract][Full Text] [Related]
33. Estimating the proportion of pathogenic variants from breast cancer case-control data: Application to calibration of ACMG/AMP variant classification criteria.
James PA; Fortuno C; Li N; Lim BWX; Campbell IG; Spurdle AB
Hum Mutat; 2022 Jul; 43(7):882-888. PubMed ID: 35191126
[TBL] [Abstract][Full Text] [Related]
34. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
36. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
[TBL] [Abstract][Full Text] [Related]
37. Frequency of Pathogenic Germline Variants in
Petridis C; Arora I; Shah V; Moss CL; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Cancer Epidemiol Biomarkers Prev; 2019 Jul; 28(7):1162-1168. PubMed ID: 31263054
[TBL] [Abstract][Full Text] [Related]
38. Rare variants in the ATM gene and risk of breast cancer.
Goldgar DE; Healey S; Dowty JG; Da Silva L; Chen X; Spurdle AB; Terry MB; Daly MJ; Buys SM; Southey MC; Andrulis I; John EM; ; ; Khanna KK; Hopper JL; Oefner PJ; Lakhani S; Chenevix-Trench G
Breast Cancer Res; 2011 Jul; 13(4):R73. PubMed ID: 21787400
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
40. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
Li H; Engel C; de la Hoya M; Peterlongo P; Yannoukakos D; Livraghi L; Radice P; Thomassen M; Hansen TVO; Gerdes AM; Nielsen HR; Caputo SM; Zambelli A; Borg A; Solano A; Thomas A; Parsons MT; Antoniou AC; Leslie G; Yang X; Chenevix-Trench G; Caldes T; Kwong A; Pedersen IS; Lautrup CK; John EM; Terry MB; Hopper JL; Southey MC; Andrulis IL; Tischkowitz M; Janavicius R; Boonen SE; Kroeldrup L; Varesco L; Hamann U; Vega A; Palmero EI; Garber J; Montagna M; Van Asperen CJ; Foretova L; Greene MH; Selkirk T; Moller P; Toland AE; Domchek SM; James PA; Thorne H; Eccles DM; Nielsen SM; Manoukian S; Pasini B; Caligo MA; Lazaro C; Kirk J; Wappenschmidt B; Spurdle AB; Couch FJ; Schmutzler R; Goldgar DE; ;
Genet Med; 2022 Jan; 24(1):119-129. PubMed ID: 34906479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]